Nepafenac Compared to Placebo for Ocular Pain and Inflammation

Inclusion Criteria: * Adult Chinese subjects, 18 years of age or older, of either sex who have a cataract, and are expected to undergo cataract extraction with the implantation of a posterior chamber intraocular lens; * Study eye of subjects, who in the opinion of the Investigator, will have improvement in best-corrected visual acuity after surgery; * Subjects should be able to understand and sign an informed consent that has been approved by an Independent Ethics Committee; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Use of topical ocular or systemic steroids within 14 days prior to surgery; * Use of topical ocular or systemic non-steroidal anti-inflammatory drugs within 7 days of surgery, except an allowed daily dose of baby aspirin (81 mg); * Subjects planning to have cataract surgery in their fellow, non-study eye prior to the 14 day postoperative study visit; * Any intraocular inflammation or ocular pain greater than Grade 0 in the study eye that is present during the baseline slit-lamp exam; * Women of childbearing potential (those who are not surgically sterilized or post menopausal) may not participate in the study if any of the following conditions exist: * they are breast feeding; * they have a positive urine pregnancy test at baseline; * they are not willing to undergo a urine pregnancy test upon exiting the study; * they intend to become pregnant during the duration of the study; or, * they do not agree to using adequate birth control methods for the duration of the study. * Any abnormality that prevents reliable tonometry; * Planned multiple procedures during cataract/IOL implantation surgery; * Lens pseudoexfoliation syndrome with glaucoma or zonular compromise; * Previous ocular trauma to the operative eye; * A history of chronic or recurrent inflammatory eye disease; * Ocular infection or ocular pain; * Proliferative diabetic retinopathy; * Uncontrolled diabetes mellitus; * Congenital ocular anomaly; * Iris atrophy in the operative eye; * A nonfunctional fellow eye; * Use of an investigational intraocular lens; * Participation in any other clinical study within 30 days before surgery; * Known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory agents, or to any component of the study medication; * Subjects with known bleeding tendencies, or who are receiving medications that may prolong bleeding time, may be enrolled at the physician's discretion; continuation of previous therapy for these subjects will be left to the judgment of the physician; * The fellow eye of an individual currently or previously enrolled in the study; * Subjects using a topical ophthalmic prostaglandin; * Subjects, who in the opinion of the investigator, might be at increased risk of complications from topical NSAIDs; * Other protocol-defined exclusion criteria may apply.